24 Jan 2021, Edition - 2021, Sunday
Merck Foundation Partners With National Cancer Institute and Ministry of Higher Education of Egypt to Train African Oncologists
September 5, 2019
Business Wire India
- Dr. Rasha Kelej, CEO of Merck Foundation conducts a special meeting with Ministry of Higher Education, Egypt; National Cancer Institute, Cairo and African Ambassadors of Guinea Conakry, Ghana, Kenya, Sierra Leone, Liberia, Malawi and Zambia to discuss Merck Foundation’s Cancer Access Program & the two year and half Master Degree in Medical Oncology for African Doctors from 12 countries.
- Merck Foundation commits to improve access to quality and equitable cancer care in Africa.
, the philanthropic arm of Merck KGaA Germany conducted a special meeting with Ministry of Higher Education, Egypt
; National Cancer Institute, Cairo
and African Ambassadors
of Guinea Conakry, Ghana, Kenya, Sierra Leone, Liberia, Malawi and Zambia.
The meeting was chaired by Dr. Rasha Kelej, CEO of Merck Foundation.
“The purpose of this important meeting was to discuss the Merck Foundation’s Cancer Access Program
and to define a process to facilitate the enrollment of the selected African Doctors from their respective countries into the two and half year Master Degree of Medical Oncology at National Cancer Institute, Cairo University
,” emphasized Dr. Rasha Kelej.
A special committee consisting of Merck Foundation
, Foreign Students Department of Ministry of High Education, Egypt
; African Students from five countries
and Academic Members
of National Cancer Institute, Cairo
discussed the challenges and solutions to improve the impact of the program for the next five years.
“More than 20 candidates from more than 12 countries are expected to join this program, annually.
We are committed to lead Africa to a better future through shaping the landscape of Cancer care in the continent. My special thanks to Ministry of Higher Education, Egypt; National Cancer Institute and Cairo University for making this meeting a great success,” added Dr. Rasha Kelej.